1. 249 CONNECT MDS AND AML: THE MYELODYSPLASTIC SYNDROMES (MDS) AND ACUTE MYELOID LEUKEMIA (AML) DISEASE REGISTRY. Issue 1 (April 2015) Authors: Steensma, D.; Abedi, M.; Bejar, R.; Cogle, C.; Foucar, K.; Garcia-Manero, G.; George, T.; Grinblatt, D.; Komrokji, R.; Maciejewski, J.; Pollyea, D.; Roboz, G.; Savona, M.; Scott, B.; Sekeres, M.; Thompson, M.; Sugrue, M.; Swern, A.; Nifenecker, M.; Erba, H. Journal: Leukemia research Issue: Volume 39:Issue 1(2015:Jan.) Page Start: S124 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P492: TAMIBAROTENE IN COMBINATION WITH VENETOCLAX AND AZACITIDINE IN PREVIOUSLY UNTREATED ADULT PATIENTS SELECTED FOR RARA-POSITIVE AML WHO ARE INELIGIBLE FOR STANDARD INDUCTION THERAPY (SELECT AML-1). (23rd June 2022) Authors: Stein, E.; de Botton, S.; Pigneux, A.; McMahon, C.; Ball, B.; Borthakur, G.; Eghtedar, A.; Kambhampati, S.; Tache, J.; Wang, E.; Kelley, H.; Volkert, A.; Baker, K.; Kang-Fortner, Q.; Hodgson, G.; Madigan, C.; Warlick, E.; Roth, D.; Kelly, M.; Pollyea, D. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 391 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. P584: OVERALL SURVIVAL WITH INTENSIVE CHEMOTHERAPY (IC) VS NON-IC IN PATIENTS (PTS) WITH NEWLY DIAGNOSED (ND) AML FROM THE CONNECT® MYELOID DISEASE REGISTRY INELIGIBLE FOR RANDOMIZED CLINICAL TRIALS (RCT). (23rd June 2022) Authors: Erba, H.; Pollyea, D.; Sekeres, M.; Garcia-Manero, G.; Seiter, K.; DeGutis, I.; Kiselev, P.; McBride, A.; Yu, E.; Roboz, G. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 483 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Topic: AS08-Treatment/AS08b-Current treatment options – Lower risk MDS: PHASE 1 STUDY EVALUATING LOW-DOSE (LD) ORAL DECITABINE/CEDAZURIDINE (ASTX727) IN LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS) PATIENTS. (May 2023) Authors: Garcia-Manero, G.; Bachiashvili, K.; Amin, H.; Traer, E.; Pollyea, D.; Sallman, D.; Al-Kali, A.; Cripe, L.; Berdeja, J.; Griffiths, E.; Mohan, S.; Vachhani, P.; Sano, Y.; Oganesian, A.; Keer, H.; Yacoub, A. Journal: Leukemia research Issue: Volume 128(2023)Supplement Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Topic: AS08-Treatment/AS08f-Clinical trials – Phase II-III: RANDOMIZED PHASE 2 STUDY TO ASSESS SAFETY AND EFFICACY OF LOW-DOSE (LD) ORAL DECITABINE/CEDAZURIDINE (ASTX727) IN LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS) PATIENTS: INTERIM SAFETY ANALYSIS. (May 2023) Authors: Garcia-Manero, G.; Bachiashvili, K.; Griffiths, E.; Traer, E.; Saini, L.; Amin, H.; Zeidan, A.; Mohan, S.; Lübbert, M.; Maness, L.; Foran, J.; Selleslag, D.; Xicoy, B.; Pollyea, D.; Sallman, D.; Al-Kali, A.; Berdeja, J.; Al-Ali, H.; Zhu, N.; Lopez, P. Font Journal: Leukemia research Issue: Volume 128(2023)Supplement Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗